iShares US Pharmaceuticals ETF

IHE

Market cap $1.27B

The iShares U.S. Pharmaceuticals ETF is larger by assets under management and offers a higher trailing dividend yield. The State Street SPDR S&P Pharmaceuticals ETF has delivered higher one-year returns but experienced a much steeper maximum drawdown over five years.

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on May 1, 2006.

JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.

The iShares U.S. Pharmaceuticals ETF (IHE) offers a lower expense ratio and a significantly higher dividend yield than the iShares Biotechnology ETF (IBB). IBB offers broader diversification, with 248 holdings compared to just 56 for IHE.

The iShares U.S. Pharmaceuticals ETF (IHE) charges a lower expense ratio and pays a higher dividend than the Invesco Pharmaceuticals ETF (PJP). IHE is heavily concentrated in its two largest holdings, while PJP spreads its bets more evenly across the sector's biggest names.

Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and higher dosing—effectively extends product lifecycles and drives shareholder value.

iShares U.S. Pharmaceuticals ETF offers a significantly higher dividend yield and lower volatility than State Street SPDR S&P Biotech ETF. While State Street SPDR S&P Biotech ETF delivered stronger 1-year returns, iShares U.S. Pharmaceuticals ETF showed much greater resilience with a shallower maximum drawdown.

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

iShares U.S. Pharmaceuticals ETF provides more cost-efficient access to the healthcare sector with a lower expense ratio and a higher dividend yield Simplify Health Care ETF employs an active management strategy focused on innovation and donates its net profits to breast cancer research iShares U.S. Pharmaceuticals ETF has delivered higher total returns over the past year while maintaining lower price volatility than its peer

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.